Here are eight new shortages to know about, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists:
Basiliximab injection: There is not enough supply for usual ordering because of manufacturing delays. Novartis has two allocated presentations of the drug, which prevents kidney transplant rejection.
Bisoprolol fumarate; hydrochlorothiazide tablet: Teva Pharmaceuticals USA discontinued three presentations of the hypertension drug July 26.
Cyanocobalamin spray: On July 12, Endo Pharmaceuticals discontinued one presentation of the vitamin B12 supplement.
Disulfiram tablet: There are four available presentations of the alcohol use disorder medication, and one presentation from Alvogen is unavailable. A resupply date was not provided.
Esmolol injection: Six presentations of the medication, which is approved to treat abnormal heart beats, are in shortage among five manufacturers. Most companies did not share a release date, but Viatris expects more supply in August. Eleven presentations are available.
Estradiol cypionate injection: Pfizer, the sole supplier of the estrogen product, said its vials are on back order because of manufacturing delays. Supply is predicted to rebound in October.
Indocyanine green: The cyanine dye is used for medical diagnostics. There is insufficient supply for usual ordering as Hub Pharmaceuticals reports a manufacturing delay. The product is on allocation, and no release date was shared.
Orphenadrine citrate injection: There are no available presentations of the muscle relaxer. Hikma Pharmaceuticals and Sagent Pharmaceuticals expect the shortage to end between late July and early August.
